Evidence for association of hyperprolinemia with schizophrenia and a measure of clinical outcome

Schizophrenia Research

Volumn 131, Issue 1-3, 2011, Pages 139-145

  Clelland, Catherine L ^a   Read, Laura L ^b,c   Baraldi, Amanda N ^c   Bart, Corinne P ^c   Pappas, Carrie A ^c   Panek, Laura J ^c   Nadrich, Robert H ^b,d   Clelland, James D ^b,c  

^a NewYork Presbyterian Hospital   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^d BELLEVUE HOSPITAL CENTER   (United States)

Author keywords

Etiology; Intermediate phenotype; Neuromodulator; Outcome; PRODH; Proline

Indexed keywords

ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIVIRUS AGENT; ARIPIPRAZOLE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PROLINE; QUETIAPINE; RISPERIDONE; STEROID;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CASE CONTROL STUDY; CLINICAL FEATURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPERPROLINEMIA; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; ONSET AGE; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT CARE; PHENOTYPE; POSITIVE SYNDROME; PRIORITY JOURNAL; RACE; RISK FACTOR; SCHIZOPHRENIA; SCORING SYSTEM; SECONDARY ANALYSIS; SYMPTOM; TIME;

ADOLESCENT; ADULT; AGED; AMINO ACID METABOLISM, INBORN ERRORS; ANALYSIS OF VARIANCE; BRIEF PSYCHIATRIC RATING SCALE; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROLINE; PROLINE OXIDASE; SCHIZOPHRENIA; VALPROIC ACID; YOUNG ADULT;

EID: 80051782495     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.05.006     Document Type: Article

References (42)

1. Afenjar A., Moutard M.L., Doummar D., Guet A., Rabier D., Vermersch A.I., et al. Early neurological phenotype in 4 children with biallelic PRODH mutations. Brain Dev. 2007, 29(9):547-552.
2. Baxter C.F., Baldwin R.A., Davis J.L., Flood J.F. High proline levels in the brains of mice as related to specific learning deficits. Pharmacol. Biochem. Behav. 1985, 22(6):1053-1059.
3. Bender H.U., Almashanu S., Steel G., Hu C.A., Lin W.W., Willis A., et al. Functional consequences of PRODH missense mutations. Am. J. Hum. Genet. 2005, 76(3):409-420.
4. Braff D., Stone C., Callaway E., Geyer M., Glick I., Bali L., et al. Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 1978, 15(4):339-343.
5. Bremer H.J., Duran M., Kamerling J.P., Przyrembel H., Wadman S.K., et al. Disturbances of Amino Acid Metabolism: Clinical Chemistry and Diagnosis 1981, Urban & Schwarzenberg, Inc., Baltimore-Munich.
6. Centorrino F., Goren J.L., Hennen J., Salvatore P., Kelleher J.P., Baldessarini R.J. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am. J. Psychiatry 2004, 161(4):700-706.
7. Cohen S.M., Nadler J.V. Proline-induced potentiation of glutamate transmission. Brain Res. 1997, 761(2):271-282.
8. Cohen S.M., Nadler J.V. Proline-induced inhibition of glutamate release in hippocampal area CA1. Brain Res. 1997, 769(2):333-339.
9. Davis J.L., Pico R.M., Flood J.F. Differences in learning between hyperprolinemic mice and their congenic controls. Behav. Neural Biol. 1987, 48(1):128-137.
10. Dingman W., Sporn M.B. The penetration of proline and proline derivatives into brain. J. Neurochem. 1959, 4(2):148-153.
11. Efron M.L. Familial hyperprolinemia. Report of a second case, associated with congenital renal malformations, hereditary hematuria and mild mental retardation, with demonstration of an enzyme defect. N. Engl. J. Med. 1965, 272:1243-1254.
12. Flynn M.P., Martin M.C., Moore P.T., Stafford J.A., Fleming G.A., Phang J.M. Type II hyperprolinaemia in a pedigree of Irish travellers (nomads). Arch. Dis. Child. 1989, 64(12):1699-1707.
13. Fremeau R.T., Caron M.G., Blakely R.D. Molecular cloning and expression of a high affinity L-proline transporter expressed in putative glutamatergic pathways of rat brain. Neuron 1992, 8(5):915-926.
14. Gogos J.A., Santha M., Takacs Z., Beck K.D., Luine V., Lucas L.R., et al. The gene encoding proline dehydrogenase modulates sensorimotor gating in mice. Nat. Genet. 1999, 21(4):434-439.
15. Goodman B.K., Rutberg J., Lin W.W., Pulver A.E., Thomas G.H. Hyperprolinaemia in patients with deletion (22)(q11.2) syndrome. J. Inherit. Metab. Dis. 2000, 23(8):847-848.
16. Guilmatre A., Legallic S., Steel G., Willis A., Di Rosa G., Goldenberg A., et al. Type I hyperprolinemia: genotype/phenotype correlations. Hum. Mutat. 2010, 31(8):961-965.
17. Jacquet H., Raux G., Thibaut F., Hecketsweiler B., Houy E., Demilly C., et al. PRODH mutations and hyperprolinemia in a subset of schizophrenic patients. Hum. Mol. Genet. 2002, 11(19):2243-2249.
18. Jacquet H., Berthelot J., Bonnemains C., Simard G., Saugier-Veber P., Raux G., et al. The severe form of type I hyperprolinaemia results from homozygous inactivation of the PRODH gene. J. Med. Genet. 2003, 40(1):e7.
19. Jacquet H., Demily C., Houy E., Hecketsweiler B., Bou J., Raux G., et al. Hyperprolinemia is a risk factor for schizoaffective disorder. Mol. Psychiatry 2005, 10(5):479-485.
20. Karayiorgou M., Gogos J.A. The molecular genetics of the 22q11-associated schizophrenia. Brain Res. Mol. Brain Res. 2004, 132(2):95-104.
21. Karayiorgou M., Simon T.J., Gogos J.A. 22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia. Nat. Rev. Neurosci. 2010, 11(6):402-416.
22. Kempf L., Nicodemus K.K., Kolachana B., Vakkalanka R., Verchinski B.A., Egan M.F., et al. Functional polymorphisms in PRODH are associated with risk and protection for schizophrenia and fronto-striatal structure and function. PLoS Genet. 2008, 4(11):e1000252.
23. McDonald-McGinn D.M., et al. The 22q11.2 deletion in African-American patients: an underdiagnosed population?. Am. J. Med. Genet. A 2005, 134(3):242-246.
24. Mitsubuchi H., et al. Inborn errors of proline metabolism. J. Nutr. 2008, 138(10):2016S-2020S.
25. Murphy K.C., Jones L.A., Owen M.J. High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch. Gen. Psychiatry 1999, 56(10):940-945.
26. Nadler J.V. Sodium-dependent proline uptake in the rat hippocampal formation: association with ipsilateral-commissural projections of CA3 pyramidal cells. J. Neurochem. 1987, 49(4):1155-1160.
27. Nadler J.V., Bray S.D., Evenson D.A. Autoradiographic localization of proline uptake in excitatory hippocampal pathways. Hippocampus 1992, 2(3):269-278.
28. Nickolson V.J. On" and off" responses of K+-induced synaptosomal proline release: involvement of the sodium pump. J. Neurochem. 1982, 38(1):289-292.
29. Paterlini M., Zakharenko S.S., Lai W.S., Qin J., Zhang H., Mukai J.W., Zakharenko S.S., Lai W.S., Qin J., Zhang H., Mukai J.W., et al. Transcriptional and behavioral interaction between 22q11.2 orthologs modulates schizophrenia-related phenotypes in mice. Nat. Neurosci. 2005, 8(11):1586-1594.
30. Phang J.M., Hu C.A., Valle D. Disorders of Proline and Hydroxyproline Metabolism 2001, McGraw-Hill, New York. Eigth edition.
31. Rabinowitz J., Levine S.Z., Hafner H. A population based elaboration of the role of age of onset on the course of schizophrenia. Schizophr. Res. 2006, 88(1-3):96-101.
32. Rao M.L., Gross G., Strebel B., Bräunig P., Huber G., KlosterkÖtter J. Serum amino acids, central monoamines, and hormones in drug-naive, drug-free, and neuroleptic-treated schizophrenic patients and healthy subjects. Psychiatry Res. 1990, 34:243-257.
33. Raux G., Bumsel E., Hecketsweiler B., van Amelsvoort T., Zinkstok J., Manouvrier-Hanu S., et al. Involvement of hyperprolinemia in cognitive and psychiatric features of the 22q11 deletion syndrome. Hum. Mol. Genet. 2007, 16(1):83-91.
34. Renick S.E., Kleven D.T., Chan J., Stenius K., Milner T.A., Pickel V.M., et al. The mammalian brain high-affinity L-proline transporter is enriched preferentially in synaptic vesicles in a subpopulation of excitatory nerve terminals in rat forebrain. J. Neurosci. 1999, 19(1):21-33.
35. Scambler P.J. The 22q11 deletion syndromes. Hum. Mol. Genet. 2000, 9(16):2421-2426.
36. Shafqat S., Faircloth M., Henzi V.A., Whitney K.D., Yang-Feng T.L., Seldin M.F., et al. Human brain-specific L-proline transporter: molecular cloning, functional expression, and chromosomal localization of the gene in human and mouse genomes. Mol. Pharmacol. 1995, 48(2):219-229.
37. Shanti N.D., Shashikumar K.C., Desai P.V. Influence of proline on rat brain activities of alanine aminotransferase, aspartate aminotransferase and acid phosphatase. Neurochem. Res. 2004, 29(12):2197-2206.
38. Tomiya M., Fukushima T., Watanabe H., Fukami G., Fujisaki M., Iyo M., et al. Alterations in serum amino acid concentrations in male and female schizophrenic patients. Clin. Chim. Acta 2007, 380(1-2):186-190.
39. Velaz-Faircloth M., Guadano-Ferraz A., Henzi V.A., Fremeau R.T. Mammalian brain-specific L-proline transporter. Neuronal localization of mRNA and enrichment of transporter protein in synaptic plasma membranes. J. Biol. Chem. 1995, 270(26):15755-15761.
40. Walter H., Schlaff W.B., Lesch O.M., Vitek L., Zima T., Hartl D., et al. Breath alcohol level and plasma amino acids: a comparison between older and younger chronic alcohol-dependent patients. Alcohol Alcohol. 2008, 43(6):653-657.
41. Wassef A.A., Winkler D.E., Roache A.L., Abobo V.B., Lopez L.M., Averill J.P., et al. Lower effectiveness of divalproex versus valproic acid in a prospective, quasi-experimental clinical trial involving 9260 psychiatric admissions. Am. J. Psychiatry 2005, 162(2):330-339.
42. Yoneda Y., Roberts E. A new synaptosomal biosynthetic pathway of proline from ornithine and its negative feedback inhibition by proline. Brain Res. 1982, 239(2):479-488.